On Jun. 23, 2020, FibroGen announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute coronavirus 2019 (COVID-19) infection. This multicenter trial will be conducted in the U.S. and will enroll approximately 130 patients with COVID-19.